Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
NCT02948088 · View on ClinicalTrials.gov ↗
Study Summary
TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of d-TGCT. This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.
Conditions Studied
Study Locations (15)
Other
- Medizinische Universität Graz — Graz
- CHU Nantes — Nantes
- Westdeutsches Tumorzentrum — Essen
- Istituto Ortopedico Rizzoli — Bologna
- Istituto Nazionale Tumori-Foundazione IRCCS — Milan
- Leiden University Medical Center — Leiden
- Radboud universitair medisch centrum — Nijmegen
- Hospital Sant Pau — Barcelona
- Hospital Universitario Virgen del Rocio — Seville
- The Royal Marsden Hospital — London
- Nuffield Orthopaedic Centre — Oxford
California
- David Geffen School of Medicine at UCLA — Los Angeles
- University of California San Francisco — San Francisco
New York
- Memorial Sloan Kettering Cancer Center — New York
Texas
- University of Texas MD Anderson Cancer Center — Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2021-03-11 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02948088
The ClinicalTrials.gov registry entry for NCT02948088 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 157 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Giant Cell Tumors appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02948088 reports 15 study locations spanning 4 distinct geographic areas — top geographies include Other, California, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02948088 about?
NCT02948088 is a clinical study titled "Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project". TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pai...
What is the current status of trial NCT02948088?
This trial is currently completed. The enrollment target is 183 participants. The study started on 2016-11-18. Estimated completion is 2021-03-11.
What conditions does trial NCT02948088 study?
This clinical trial studies the following conditions: Giant Cell Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT02948088?
This trial is sponsored by Daiichi Sankyo, which has 157 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02948088 being conducted?
This trial has 15 study locations across California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.